Hee Yeon Kim

Hee Yeon Kim

Auto-generated profile, based on publicly available information

Hee Yeon Kim

Busan Paik Hospital, Inje University College of Medicine

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
NANguyen Ky Anh
Nguyen Ky Anh
ALAnbok Lee
Anbok Lee
NPNguyen Ky Phat
Nguyen Ky Phat
NYNguyen Thi Hai Yen
Nguyen Thi Hai Yen
NTNguyen Quang Thu
Nguyen Quang Thu
NLNguyen Phuoc Long
Nguyen Phuoc Long
There is an urgent need for better biomarkers for the detection of early-stage breast cancer. Utilizing untargeted metabolomics and lipidomics in conjunction with advanced data mining approaches for metabolism-centric biomarker discovery and validation may enhance the identification and validation of novel biomarkers for breast cancer screening. In this study, we employed a multimodal omics approach to identify and validate potential biomarkers capable of differentiating between patients with breast cancer and those with benign tumors. Our findings indicated that ether-linked phosphatidylcholine exhibited a significant difference between invasive ductal carcinoma and benign tumors, including cases with inconsistent mammography results. We observed alterations in numerous lipid species, including sphingomyelin, triacylglycerol, and free fatty acids, in the breast cancer group. Furthermore, we identified several dysregulated hydrophilic metabolites in breast cancer, such as glutamate, glycochenodeoxycholate, and dimethyluric acid. Through robust multivariate receiver operating characteristic analysis utilizing machine learning models, either linear support vector machines or random forest models, we successfully distinguished between cancerous and benign cases with promising outcomes. These results emphasize the potential of metabolic biomarkers to complement other criteria in breast cancer screening. Future studies are essential to further validate the metabolic biomarkers identified in our study and to develop assays for clinical applications.

1 January 2019 in Journal of Breast Cancer
Verified
Journal Article
Open access
PDF file
HKHee Yeon Kim
Hee Yeon Kim
TKTae Hyun Kim
Tae Hyun Kim
HYHye Kyoung Yoon
Hye Kyoung Yoon
ALAnbok Lee
Anbok Lee
Kim HY, et al. J Breast Cancer. 2019 Jul;22:e41. https://doi.org/10.4048/jbc.2019.22.e41

1 August 2021 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
NLNguyen Phuoc Long
Nguyen Phuoc Long
DHDayoung Heo
Dayoung Heo
HKHee-Yeon Kim
Hee-Yeon Kim
TKTae Hyun Kim
Tae Hyun Kim
JSJae-Gook Shin
Jae-Gook Shin
Dong Hyun KimDong Hyun Kim
Dong Hyun Kim

1 January 2022 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
ALAnbok Lee
Anbok Lee
HKHee Yeon Kim
Hee Yeon Kim
TKTae Hyun Kim
Tae Hyun Kim
KAKi Jung Ahn
Ki Jung Ahn
HCHeunglae Cho
Heunglae Cho
YCYunseon Choi
Yunseon Choi
Lee A, et al. J Korean Med Sci. 2022 Feb;37(8):e64. https://doi.org/10.3346/jkms.2022.37.e64

6 January 2022 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Open access
PDF file
HKHee Yeon Kim
Hee Yeon Kim
JCJae-Hyeog Choi
Jae-Hyeog Choi
MHMasudul Haque
Masudul Haque
JPJin Hee Park
Jin Hee Park
IKIl-Hwan Kim
Il-Hwan Kim
SPSaeGwang Park
SaeGwang Park
Human epidermal growth factor receptor type 2 (HER2)-positive breast cancer that is treated with anti-HER2/neu monoclonal antibody (mAb) is not free from late recurrences. Addition of anti-4-1BB mAb to anti-HER2/neu mAb has been demonstrated to strengthen the cytotoxic antitumor response. Our study expands on this by revealing the influence of anti-4-1BB mAb addition on the immune memory of anti-HER2/neu mAb. We designed murine breast cancer models by implanting TUBO and TUBO-P2J cell lines in mice, which were then treated with anti-HER2/neu and/or anti-4-1BB mAb. After complete surgical and/or chemical regression of the tumor, the mice were rechallenged with a second injection of cancer cells. Notably, anti-HER2/neu and anti-4-1BB mAb combination therapy had a synergistic antitumor effect at the initial treatment. However, the combination therapy did not evoke immune memory, allowing the tumors to thrive at rechallenge with reduced CD44+ expression in CD8+ T cells. Immune memory was also impaired when anti-4-1BB mAb was administered to naive CD8+ T cells but was sustained when this was administered to activated CD8+ T cells. In an attempt to resist the loss of immune memory, we controlled the dose of anti-4-1BB mAb to optimize the stimulation of activated CD8+ T cells. Immune memory was achieved with the dose regulation of anti-4-1BB mAb to 1 mg/kg in our model. Our study demonstrates the importance in understanding the adaptive immune mechanism of anti-HER2/neu and anti-4-1BB mAb combination therapy and suggests a dose optimization strategy is necessary to ensure development of successful immune memory.

1 January 2024 in Annals of Surgical Treatment and Research
Verified
Journal Article
Open access
PDF file
JPJi Sun Park
Ji Sun Park
YKYoung Suk Kim
Young Suk Kim
HKHee Yeon Kim
Hee Yeon Kim
YCYunseon Choi
Yunseon Choi
Park JS, et al. Ann Surg Treat Res. 2024 Jun;106(6):337-343. https://doi.org/10.4174/astr.2024.106.6.337